Literature DB >> 16111583

Rectal fistulas after prostate brachytherapy.

Audrey Tran1, Kent Wallner, Gregory Merrick, Jergen Seeberger, Julius Armstrong, Amy Mueller, William Cavanagh, Daniel Lin, Wayne Butler.   

Abstract

PURPOSE: To compare the rectal and prostatic radiation doses for a prospective series of 503 patients, 44 of whom developed persistent rectal bleeding, and 2 of whom developed rectal-prostatic fistulas. METHODS AND MATERIALS: The 503 patients were randomized and treated by implantation with 125I vs. 103Pd alone (n = 290) or to 103Pd with 20 Gy vs. 44 Gy supplemental external beam radiotherapy (n = 213) and treated at the Puget Sound Veterans Affairs Medical Center (n = 227), Schiffler Cancer Center (n = 242) or University of Washington (n = 34). Patients were treated between September 1998 and October 2001 and had a minimum of 24 months of follow-up. The patient groups were treated concurrently. Treatment-related morbidity was monitored by mailed questionnaires, using standard American Urological Association and Radiation Therapy Oncology Group criteria, at 1, 3, 6, 12, 18, and 24 months. Patients who reported Grade 1 or greater Radiation Therapy Oncology Group rectal morbidity were interviewed by telephone to clarify details regarding their rectal bleeding. Those who reported persistent bleeding, lasting for >1 month were included as having Grade 2 toxicity. Three of the patients with rectal bleeding required a colostomy, two of whom developed a fistula. No patient was lost to follow-up. The rectal doses were defined as the rectal volume in cubic centimeters that received >50%, 100%, 200%, or 300% of the prescription dose. The rectum was considered as a solid structure defined by the outer wall, without attempting to differentiate the inner wall or contents.
RESULTS: Persistent rectal bleeding occurred in 44 of the 502 patients, 32 of whom (73%) underwent confirmatory endoscopy. In univariate analysis, multiple parameters were associated with late rectal bleeding, including all rectal brachytherapy indexes. In multivariate analysis, however, only the rectal volume that received >100% of the dose was significantly predictive of bleeding. Rectal fistulas occurred in 2 patients (0.4%), both of whom had received moderate rectal radiation doses and extensive intervention for rectal bleeding.
CONCLUSION: Partly on the basis of data from others and data presented here, we believe that the incidence of rectal fistulas can be much lower than in our series. High rectal radiation doses should be avoided a priori, to minimize the likelihood of rectal bleeding, and hence the likelihood that invasive procedures will be performed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111583     DOI: 10.1016/j.ijrobp.2005.01.021

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds.

Authors:  V Morillo; J L Guinot; I Tortajada; J V Ricós; L Arribas; M Maroñas; M Estornell; J Casanova
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

2.  Canadian prostate brachytherapy in 2012.

Authors:  Mira Keyes; Juanita Crook; W James Morris; Gerard Morton; Tom Pickles; Nawaid Usmani; Eric Vigneault
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

Review 3.  A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.

Authors:  M E Schutzer; P F Orio; M C Biagioli; D A Asher; H Lomas; D Moghanaki
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-17       Impact factor: 5.554

4.  Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer.

Authors:  E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri
Journal:  Strahlenther Onkol       Date:  2012-11-11       Impact factor: 3.621

5.  Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study.

Authors:  Michael Pinkawa; Richard Holy; Marc D Piroth; Karin Fischedick; Sandra Schaar; Dalma Székely-Orbán; Michael J Eble
Journal:  Radiat Oncol       Date:  2010-04-08       Impact factor: 3.481

6.  Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy.

Authors:  Alexandra J Stewart; Robert A Cormack; Hang Lee; Li Xiong; Jorgen L Hansen; Desmond A O'Farrell; Akila N Viswanathan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

7.  Evaluation of rectal bleeding factors associated with prostate brachytherapy.

Authors:  Manabu Aoki; Kenta Miki; Hiroshi Sasaki; Masato Kido; Jun Shirahama; Sayako Takagi; Masao Kobayashi; Chikara Honda; Chihiro Kanehira
Journal:  Jpn J Radiol       Date:  2009-12-25       Impact factor: 2.374

8.  Narrow safety range of intraoperative rectal irradiation exposure volume for avoiding bleeding after seed implant brachytherapy.

Authors:  Ryuji Nakamura; Koyo Kikuchi; Susumu Tanji; Tomonori Yabuuchi; Ikuko Uwano; Satoshi Yamaguchi; Hisanori Ariga; Tomoaki Fujioka
Journal:  Radiat Oncol       Date:  2012-01-31       Impact factor: 3.481

Review 9.  The current role of imaging for prostate brachytherapy.

Authors:  Brendan Carey; Sarah Swift
Journal:  Cancer Imaging       Date:  2007-02-28       Impact factor: 3.909

Review 10.  Focal low-dose rate brachytherapy for the treatment of prostate cancer.

Authors:  William Y Tong; Gilad Cohen; Yoshiya Yamada
Journal:  Cancer Manag Res       Date:  2013-09-13       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.